查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1980613

骨科生技藥品市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類，並預測至2026-2034年

Orthobiologics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 181 Pages | 商品交期: 請詢問到貨日

價格

骨科生技藥品市場成長要素

全球骨科生技藥品市場正經歷顯著成長，其主要促進因素包括骨骼和肌肉骨骼疾病盛行率的上升、整形外科損傷病例的增加以及再生醫學的日益普及。該市場在2025年的估值為97億美元，預計2026年將達到102.2億美元，到2034年將成長至150.6億美元，預測期內複合年成長率（CAGR）為5.00%。北美地區在2025年佔市場主導地位，市佔率高達47.69%。這主要歸功於生物製藥在骨骼相關創傷治療中的快速應用、龐大的患者群體以及大量的整形外科手術。

骨科生技藥品是由人體內天然存在的物質製成的產品，用於促進骨骼、韌帶、肌腱和肌肉的癒合。它們廣泛應用於整形外科手術中，用於修復骨缺損和促進組織再生。幹細胞移植和其他生技藥品在整形外科治療中日益廣泛的應用預計將進一步推動市場成長。

新冠疫情期間，由於患者就診量減少、醫療資源重新分配以及供應鏈中斷，市場經歷了短暫下滑。 2020年市場收入下降了10.6%，但隨著患者數量的增加、疫苗接種率的提高以及整形外科手術的恢復，市場在2021年開始復甦。到2022年，市場已恢復到疫情前的水準。強生服務公司（Johnson & Johnson Services, Inc.）的業績是最好的例證，該公司報告的淨銷售額為949.43億美元，其中整形外科產品貢獻顯著。

市場趨勢

推動市場發展的主要趨勢之一是擴大使用黏彈性移植物來延緩全膝關節置換術。黏彈性移植物能夠恢復滑液的流變特性，減輕疼痛，改善關節功能，並促進軟骨再生。研究表明，注射透明質酸治療可以將全膝關節置換術的等待時間延遲一年以上，這促使黏彈性移植物的應用日益廣泛。

市場促進因素

整形外科損傷、骨折、骨質疏鬆症和運動相關創傷的發生率不斷上升，推動了對生物製藥的需求。光是在美國，每年就有超過680萬名患者尋求整形外科損傷治療。髖部和脊椎骨折的日益增加以及交通事故的增加，也促進了市場擴張。

另一個因素是新型骨科生物製品的推出，例如同種異體移植材料、骨生長因子和合成骨替代品。例如，Royal Biologics公司於2020年推出了不含DMSO的生物細胞同種異體移植材料MAGNUS，而Biocomposites公司的抗生素緩釋骨缺損填充材獲得了CE認證。持續的產品創新確保了骨骼修復領域先進解決方案的供應，從而推動了市場成長。

市場限制因素

由於某些骨科生技藥品的臨床限制以及骨形成蛋白（BMP）相關問題，市場面臨許多限制因素。Medtronic的INFUSE是一種廣泛使用的BMP，據報其具有嚴重的副作用，包括感染疾病、泌尿系統疾病、骨骼和神經損傷以及潛在的致癌風險。其他骨科生技藥品也因組織排斥、骨形成不全和軟組織感染疾病等問題而難以廣泛應用。

市場區隔

依產品類型

  • 預計到 2026 年，黏彈性栓劑將佔 31.51% 的市場佔有率，這主要歸因於人口老化導致膝骨關節炎盛行率不斷上升。
  • 合成骨替代品預計將實現最高的複合年成長率，這主要得益於已開發地區採用率的提高以及對新產品推出的重視。
  • 由於脫鈣骨基質（DBM）和細胞同種異體移植材料具有良好的成骨性和微創應用的特點，它們也為市場做出了重大貢獻。

透過使用

  • 預計到 2026 年，脊椎融合手術將以 31.12% 的市場佔有率引領市場，這主要得益於全球脊椎手術數量的增加以及新的骨科生技藥品的核准。
  • 骨折和骨質疏鬆症的日益普遍，使得重組和骨折手術成為第二大市場。

最終用戶

  • 到 2026 年，醫院和門診手術中心 (ASC) 將佔市場主導地位，佔市場佔有率的 61.35%，這主要得益於其龐大的患者數量和大量的整形外科手術。
  • 整形外科治療領域對專業護理的需求日益成長，預計將促使專業診所的顯著成長。

區域趨勢

  • 北美：預計到 2025 年市場規模將達到 46.3 億美元，到 2026 年將達到 45.1 億美元。這主要得益於大規模的患者群體和先進的醫療保健基礎設施。
  • 歐洲：作為第二大市場，在研發投資和積極的臨床試驗結果的支持下，預計到 2026 年，德國市場規模將達到 7.5 億美元，英國規模將達到 5.3 億美元。
  • 亞太地區：由於骨科生技藥品滲透率低、患者群體龐大以及骨骼疾病盛行率不斷上升，預計該地區將實現最高的複合年成長率。到2026年，日本、中國和印度的市場規模預計將分別達到7.2億美元、5.5億美元和3億美元。
  • 拉丁美洲、中東和非洲：由於人們意識的提高、新生物製劑的引入以及醫療保健基礎設施的改善，預計將實現溫和成長。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 臨床適應症的流行病學
  • 主要國家的監管狀況
  • 新產品發布
  • 產業重大發展動態（合併、收購、合作）
  • 新冠疫情對市場的影響

第5章：2021-2034年全球骨科生技藥品市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品類型分類
    • 黏彈性補充劑
    • 骨生長因子
    • 去鈣骨基質（DBM）
    • 合成骨替代物
    • 細胞同種異體移植
    • 同種異體移植
    • 其他
  • 市場分析、洞察與預測：按應用領域分類
    • 脊椎融合手術
    • 顎顏面和牙科護理
    • 軟組織修復
    • 重組/骨折手術
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院和門診手術中心（ASC）
    • 專科診所
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美骨科生技藥品市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲骨科生技藥品市場分析、洞察與預測（2021-2034年）

  • 國家
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區骨科生技藥品市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲骨科生技藥品市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲骨科生技藥品市場分析、洞察與預測（2021-2034年）

  • 國家
    • 南非
    • GCC
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Medtronic
    • Zimmer Biomet
    • DePuy Synthes（Johnson & Johnson Services, Inc.）
    • Stryker
    • Anika Therapeutics, Inc.
    • SeaSpine
    • Bioventus
    • RTI Surgical
    • MTF Biologics
    • Arthrex, Inc.
    • Smith & Nephew
Product Code: FBI100173

Growth Factors of orthobiologics Market

The global orthobiologics market is witnessing substantial growth driven by the rising prevalence of bone and musculoskeletal disorders, increasing orthopedic injuries, and the adoption of regenerative medicine. The market was valued at USD 9.7 billion in 2025, projected to reach USD 10.22 billion in 2026, and is expected to grow to USD 15.06 billion by 2034, exhibiting a CAGR of 5.00% during the forecast period. North America dominated the market in 2025, capturing a 47.69% share, owing to rapid adoption of biologics for bone-related injuries, the large patient pool, and a high volume of orthopedic surgeries.

Orthobiologics are products derived from naturally occurring substances in the body, used to enhance the healing of bones, ligaments, tendons, and muscles. They are widely used in orthopedic procedures to repair bone defects and promote tissue regeneration. The increasing use of stem cell-based allografts and other biologics in orthopedic treatments is expected to further fuel market growth.

During the COVID-19 pandemic, the market experienced a temporary decline due to reduced patient visits, reallocation of healthcare resources, and supply chain disruptions. In 2020, the market revenue declined by 10.6%, but recovery began in 2021 with rising patient volumes, vaccination coverage, and resumption of orthopedic surgeries. By 2022, the market returned to pre-pandemic levels, as highlighted by Johnson & Johnson Services, Inc., which reported net sales of USD 94,943 million, including significant contributions from orthopedic products.

Market Trends

A major trend driving the market is the increased use of viscosupplements to delay total knee replacement procedures. Viscosupplements restore the rheological properties of synovial fluid, reduce pain, improve joint function, and promote cartilage regeneration. Studies indicate that treatment with hyaluronic acid injections can delay total knee replacement surgery by over one year, contributing to the growing adoption of viscosupplements.

Market Drivers

The rising incidence of orthopedic injuries, bone fractures, osteoporosis, and sports-related traumas is fueling the demand for orthobiologic products. In the U.S. alone, over 6.8 million patients seek treatment for orthopedic injuries annually. The increasing prevalence of hip and spinal fractures, along with road accidents, is also supporting market expansion.

Another driver is the launch of new orthobiologics products, including allografts, bone growth factors, and synthetic bone substitutes. For example, Royal Biologics launched MAGNUS, a DMSO-free viable cellular bone allograft in 2020, while Biocomposites received CE approval for antibiotic-eluting bone void fillers. Continuous product innovation ensures the availability of advanced solutions for bone repair, enhancing market growth.

Market Restraints

The market faces constraints due to clinical limitations of certain orthobiologics and issues associated with bone morphogenetic proteins (BMPs). Medtronic's INFUSE, a widely used BMP, has been associated with serious side effects such as infections, urinary problems, bone/nerve injury, and potential cancer risk. Adverse tissue reactions, incomplete bone formation, and soft tissue infections with other orthobiologics also limit widespread adoption.

Market Segmentation

By Product Type

  • Viscosupplements held a dominant share of 31.51% in 2026, driven by increasing prevalence of knee osteoarthritis among the aging population.
  • Synthetic bone substitutes are expected to record the highest CAGR due to adoption in developed regions and focus on new product launches.
  • Demineralized Bone Matrix (DBM) and cellular allografts also contribute significantly due to enhanced osteoinductive properties and minimally invasive applications.

By Application

  • Spinal fusion led the market with 31.12% share in 2026, fueled by increasing spinal surgeries globally and approvals for new orthobiologics.
  • Reconstructive & fracture surgeries accounted for the second-largest market share due to rising prevalence of fractures and osteoporosis.

By End-User

  • Hospitals & Ambulatory Surgery Centers (ASCs) dominated with 61.35% market share in 2026, supported by high patient volumes and orthopedic procedures.
  • Specialty clinics are expected to grow significantly due to increasing need for specialized care in orthopedic treatments.

Regional Insights

  • North America: Valued at USD 4.63 billion in 2025, projected to reach USD 4.51 billion in 2026, driven by large patient base and advanced healthcare infrastructure.
  • Europe: Second-largest market, with Germany reaching USD 0.75 billion and the UK USD 0.53 billion by 2026, supported by R&D investments and positive clinical trials.
  • Asia Pacific: Highest CAGR expected due to under-penetration of orthobiologics, large patient pool, and rising bone disease prevalence. Japan, China, and India are projected to reach USD 0.72, 0.55, and 0.3 billion, respectively, by 2026.
  • Latin America & Middle East & Africa: Moderate growth driven by increasing awareness, adoption of novel biologics, and improving healthcare infrastructure.

Competitive Landscape

Key players include Medtronic (Ireland), Zimmer Biomet (U.S.), DePuy Synthes (U.S.), Stryker (U.S.), Anika Therapeutics, Inc. (U.S.), SeaSpine (U.S.), Bioventus (U.S.), RTI Surgical (U.S.), MTF Biologics (U.S.), Arthrex, Inc. (U.S.), and Smith & Nephew (U.K.). Recent developments include:

  • October 2023 - Orthofix Medical launched OsteoCove, a bioactive synthetic graft.
  • June 2023 - Anika Therapeutics received FDA 510(k) clearance for Tactoset Injectable Bone Substitute.
  • March 2023 - LifeNet Health launched ViviGen MIS, a viable bone matrix for MIS spine procedures.

Conclusion

The orthobiologics market is set to grow from USD 9.7 billion in 2025 to USD 15.06 billion by 2034, driven by the increasing prevalence of orthopedic injuries, the adoption of viscosupplements, spinal fusion procedures, and the launch of innovative biologic products. While clinical limitations of certain BMPs and bone graft substitutes may restrain growth, the rising demand for advanced, minimally invasive orthopedic treatments ensures continued market expansion.

Segmentation

By Product Type

  • Viscosupplements
  • Bone Growth Factors
  • Demineralized Bone Matrix (DBM)
  • Synthetic Bone Substitutes
  • Cellular Allograft
  • Others

By Application

  • Spinal Fusion
  • Maxillofacial & Dental
  • Soft Tissue Repair
  • Reconstructive & Fracture Surgery
  • Others

By End-user

  • Hospitals & ASCs
  • Specialty Clinics
  • Others

By Geography

  • North America (By Product Type, By Application, By End-user, and By Country)
    • U.S. (By Application)
    • Canada (By Application)
  • Europe (By Product Type, By Application, By End-user, and By Country/Sub-region)
    • Germany (By Application)
    • U.K. (By Application)
    • France (By Application)
    • Italy (By Application)
    • Scandinavia (By Application)
    • Rest of Europe (By Application)
  • Asia Pacific (By Product Type, By Application, By End-user, and By Country/Sub-region)
    • China (By Application)
    • India (By Application)
    • Japan (By Application)
    • Australia (By Application)
    • Southeast Asia (By Application)
    • Rest of Asia Pacific (By Application)
  • Latin America (By Product Type, By Application, By End-user, and By Country/Sub-region)
    • Brazil (By Application)
    • Mexico (By Application)
    • Rest of Latin America (By Application)
  • Middle East & Africa (By Product Type, By Application, By End-user, and By Country/Sub-region)
    • South Africa (By Application)
    • GCC (By Application)
    • Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology of Clinical Indications
  • 4.2. Regulatory Scenario for Key Countries
  • 4.3. New Product Launches
  • 4.4. Key Industry Developments (Mergers, Acquisitions, and Partnership)
  • 4.5. Impact of COVID-19 on the Market

5. Global Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Viscosupplements
    • 5.1.2. Bone Growth Factors
    • 5.1.3. Demineralized Bone Matrix (DBM)
    • 5.1.4. Synthetic Bone Substitutes
    • 5.1.5. Cellular Allograft
    • 5.1.6. Allografts
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Spinal Fusion
    • 5.2.2. Maxillofacial & Dental
    • 5.2.3. Soft Tissue Repair
    • 5.2.4. Reconstructive & Fracture Surgery
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & ASCs
    • 5.3.2. Specialty Clinics
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Viscosupplements
    • 6.1.2. Bone Growth Factors
    • 6.1.3. Demineralized Bone Matrix (DBM)
    • 6.1.4. Synthetic Bone Substitutes
    • 6.1.5. Cellular Allograft
    • 6.1.6. Allografts
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Spinal Fusion
    • 6.2.2. Maxillofacial & Dental
    • 6.2.3. Soft Tissue Repair
    • 6.2.4. Reconstructive & Fracture Surgery
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & ASCs
    • 6.3.2. Specialty Clinics
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Application
    • 6.4.2. Canada
      • 6.4.2.1. By Application

7. Europe Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Viscosupplements
    • 7.1.2. Bone Growth Factors
    • 7.1.3. Demineralized Bone Matrix (DBM)
    • 7.1.4. Synthetic Bone Substitutes
    • 7.1.5. Cellular Allograft
    • 7.1.6. Allografts
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Spinal Fusion
    • 7.2.2. Maxillofacial & Dental
    • 7.2.3. Soft Tissue Repair
    • 7.2.4. Reconstructive & Fracture Surgery
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & ASCs
    • 7.3.2. Specialty Clinics
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. Germany
      • 7.4.1.1. By Application
    • 7.4.2. U.K.
      • 7.4.2.1. By Application
    • 7.4.3. France
      • 7.4.3.1. By Application
    • 7.4.4. Italy
      • 7.4.4.1. By Application
    • 7.4.5. Spain
      • 7.4.5.1. By Application
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Application
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Application

8. Asia Pacific Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Viscosupplements
    • 8.1.2. Bone Growth Factors
    • 8.1.3. Demineralized Bone Matrix (DBM)
    • 8.1.4. Synthetic Bone Substitutes
    • 8.1.5. Cellular Allograft
    • 8.1.6. Allografts
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Spinal Fusion
    • 8.2.2. Maxillofacial & Dental
    • 8.2.3. Soft Tissue Repair
    • 8.2.4. Reconstructive & Fracture Surgery
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & ASCs
    • 8.3.2. Specialty Clinics
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. China
      • 8.4.1.1. By Application
    • 8.4.2. India
      • 8.4.2.1. By Application
    • 8.4.3. Japan
      • 8.4.3.1. By Application
    • 8.4.4. Australia
      • 8.4.4.1. By Application
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Application
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Application

9. Latin America Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Viscosupplements
    • 9.1.2. Bone Growth Factors
    • 9.1.3. Demineralized Bone Matrix (DBM)
    • 9.1.4. Synthetic Bone Substitutes
    • 9.1.5. Cellular Allograft
    • 9.1.6. Allografts
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Spinal Fusion
    • 9.2.2. Maxillofacial & Dental
    • 9.2.3. Soft Tissue Repair
    • 9.2.4. Reconstructive & Fracture Surgery
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & ASCs
    • 9.3.2. Specialty Clinics
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Application
    • 9.4.2. Mexico
      • 9.4.2.1. By Application
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Application

10. Middle East & Africa Orthobiologics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Viscosupplements
    • 10.1.2. Bone Growth Factors
    • 10.1.3. Demineralized Bone Matrix (DBM)
    • 10.1.4. Synthetic Bone Substitutes
    • 10.1.5. Cellular Allograft
    • 10.1.6. Allografts
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Spinal Fusion
    • 10.2.2. Maxillofacial & Dental
    • 10.2.3. Soft Tissue Repair
    • 10.2.4. Reconstructive & Fracture Surgery
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Hospitals & ASCs
    • 10.3.2. Specialty Clinics
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. South Africa
      • 10.4.1.1. By Application
    • 10.4.2. GCC
      • 10.4.2.1. By Application
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Application

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Medtronic
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Zimmer Biomet
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. DePuy Synthes (Johnson & Johnson Services, Inc.)
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Stryker
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Anika Therapeutics, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. SeaSpine
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Bioventus
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. RTI Surgical
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. MTF Biologics
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Arthrex, Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Smith & Nephew
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 3: Global Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 4: Global Orthobiologics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 6: North America Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 7: North America Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 8: North America Orthobiologics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: U.S. Orthobiologics Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 10: Canada Orthobiologics Market Revenue (USD billion) Forecast, By Application, 2021-2034
  • Table 11: Europe Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 12: Europe Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 13: Europe Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 14: Europe Orthobiologics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 15: Germany Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 16: U.K. Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 17: France Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 18: Italy Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Spain Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 20: Scandinavia Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 21: Rest of Europe Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 22: Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 23: Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 24: Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 25: Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: China Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 27: India Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 28: Japan Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 29: Australia Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 30: Southeast Asia Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 31: Rest of Asia Pacific Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 32: Latin America Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 33: Latin America Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 34: Latin America Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 35: Latin America Orthobiologics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Brazil Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 37: Mexico Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 38: Rest of Latin America Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 39: Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 40: Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 41: Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 42: Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 43: South Africa Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 44: GCC Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 45: Rest of Middle East & Africa Orthobiologics Market Revenue (USD billion) Forecast, by Application, 2021-2034

List of Figures

  • Figure 1: Global Orthobiologics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Orthobiologics Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Orthobiologics Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Orthobiologics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 5: Global Orthobiologics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 7: North America Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 8: North America Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 10: North America Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 11: North America Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 12: North America Orthobiologics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Orthobiologics Market Value Share (%), By Country, 2025
  • Figure 14: Europe Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 15: Europe Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 16: Europe Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 18: Europe Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 19: Europe Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Orthobiologics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Orthobiologics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 23: Asia Pacific Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 24: Asia Pacific Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Orthobiologics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Orthobiologics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 31: Latin America Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 32: Latin America Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Latin America Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 35: Latin America Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 36: Latin America Orthobiologics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Orthobiologics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Orthobiologics Market Value (USD billion), by Product Type, 2025 & 2034
  • Figure 39: Middle East & Africa Orthobiologics Market Value Share (%), by Product Type, 2025
  • Figure 40: Middle East & Africa Orthobiologics Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Orthobiologics Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Orthobiologics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 43: Middle East & Africa Orthobiologics Market Value Share (%), by End-user, 2025
  • Figure 44: Middle East & Africa Orthobiologics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Orthobiologics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Orthobiologics Market Share (%), By Company, 2025